1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Kaken Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4521   JP3207000005

KAKEN PHARMACEUTICAL CO., LTD.

(4521)
  Report
Delayed Japan Exchange  -  02:00 2022-07-01 am EDT
3810.00 JPY   -0.13%
05/31KAKEN PHARMACEUTICAL : Submission of Marketing Authorization Application for efinaconazole in Europe
PU
05/25Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
CI
05/25Kaken Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 30, 2022; Provides Second Quarter and Fiscal Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2023
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Kaken Pharmaceutical : Has Filed an Application in Japan for Regulatory Approval of KMW-1

06/28/2021 | 12:41am EDT

Tokyo, June 28, 2021 - Kaken Pharmaceutical Co., Ltd. ('Kaken', head office Bunkyo-ku, Tokyo; President and Representative Director Hiroyuki Horiuchi) announces that it has submitted a new drug application to Japan's Ministry of Health, Labour and Welfare to seek manufacturing and marketing approval of KMW-1 for the removal of burn eschar.

KMW-1 is a topical agent composed of a concentrate of proteolytic enzymes extracted from the stem of the pineapple plant. KMW-1 provides selective and quick removal of dead or damaged tissues, known as eschar, in approximately four hours after application, without harming the surrounding healthy tissues.

In April 2016, Kaken entered into an exclusive licensing agreement with MediWound Ltd., based in Israel, and has developed KMW-1, which is available in certain countries under the brand name NexoBrid®. The Phase 3 clinical trial in Japan, which enrolled patients with deep partial and full-thickness burn, has demonstrated a favorable efficacy and safety profile. If KMW-1 is approved, it would provide a new treatment option for burn patients by enabling non-invasive removal of eschar.

About the removal of burn eschar and KMW-1

Dead or damaged tissues from burn are known as eschar, and its removal or 'debridement' is a critical first step in the successful healing of severe burns. Under the current standard care, burn eschar is removed by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissues.

KMW-1 selectively removes eschar within 4 hours after application without harming the surrounding healthy tissues. KMW-1 is expected to alleviate burden on medical professionals and patients.

NexoBrid® has received marketing authorization in Europe, Israel, Argentina, South Korea, Russia, and other countries.

KMW-1 was designated as an orphan drug in Japan in February 2021.

Back to list

Disclaimer

Kaken Pharmaceutical Co. Ltd. published this content on 28 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 June 2021 04:40:02 UTC.


© Publicnow 2021
All news about KAKEN PHARMACEUTICAL CO., LTD.
05/31KAKEN PHARMACEUTICAL : Submission of Marketing Authorization Application for efinaconazole..
PU
05/25Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Y..
CI
05/25Kaken Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended Ma..
CI
05/11Kaken Pharmaceutical Co., Ltd. announces an Equity Buyback for 350,000 shares, represen..
CI
05/11Kaken Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
03/30KAKEN PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
03/29KAKEN PHARMACEUTICAL : Announcement on Recording of Extraordinary Losses and Revisions to ..
PU
02/15KAKEN PHARMACEUTICAL : [Delayed][Summary]Consolidated Financia..
PU
02/15Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Y..
CI
02/15Kaken Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Fiscal Year ..
CI
More news
Financials
Sales 2022 76 000 M 562 M 562 M
Net income 2022 9 200 M 68,0 M 68,0 M
Net Debt 2022 - - -
P/E ratio 2022 15,7x
Yield 2022 3,94%
Capitalization 144 B 1 065 M 1 065 M
Capi. / Sales 2022 1,90x
Capi. / Sales 2023 2,03x
Nbr of Employees 1 215
Free-Float 69,1%
Chart KAKEN PHARMACEUTICAL CO., LTD.
Duration : Period :
Kaken Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KAKEN PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 3 810,00 JPY
Average target price 3 200,00 JPY
Spread / Average Target -16,0%
EPS Revisions
Managers and Directors
Hiroyuki Horiuchi Manager-Hiroshima Branch
Tetsuo Onuma Director & General Manager-Sales
Keiko Kamibeppu Independent Outside Director
Shoichiro Takagi Independent Outside Director
Yasutomo Inoue Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
KAKEN PHARMACEUTICAL CO., LTD.-9.50%1 065
JOHNSON & JOHNSON3.76%472 389
PFIZER, INC.-11.21%293 506
ELI LILLY AND COMPANY17.38%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782